Search the site for any medical term or simply browse by disease topic. Access all the information you need in one place, when you need it, how you want it and for free!
Launch of accredited Type 1 Childhood Diabetes CME
A new EACCME-accredited CME activity Individual Patient Management in Type 1 Childhood Diabetes has launched on epgonline.org. Intended for medical professionals involved in the management of young patients with type 1 diabetes, this module consists of six sessions, each covering a different aspect of managing psychosocial issues in type 1 childhood diabetes.
Explore at your own pace and test your knowledge using the interactive learning exercises. The activity is totally free, and on completion you will be awarded 1 European CME credit (ECMEC).
Anti-Infectives Knowledge Network (AIKN) CDI Updates
Recently updated with new reports and policy updates as well as key perspectives on Clostridium difficile infection (CDI), the Anti-Infectives Knowledge Network shares expertise and experience in the area of anti-infectives.
This educational resource is an initiative by Astellas Pharma EMEA. Please remember to return often to read the news, clinical insights, and essential information from the latest anti-infective congresses.
January 2015 FDX/15/0003/EU
This free CME activity covers the best practice management of nocturnal enuresis through three case study-led modules, including a more severe and complex patient scenario. It is intended for Urologists, Paediatricians, Primary Care Providers and General Practitioners looking to improve their understanding and management of bedwetting.
Accredited Obesity CME
The EACCME accredited European Obesity Initiative eCME module – Understanding Obesity, is freely accessible to healthcare professionals. Upon successful completion, participants will be awarded 2 European CME credits (ECMECs) and have a broad understanding of the epidemiology, contributory factors and management options for patients with obesity.
Type 2 Diabetes accredited CME
‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ is EACCME accredited and awarded 1 European CME credit (ECMEC). There are 3 modules:
- A Review of Newer Therapies for Type 2 Diabetes in Combination with Insulin; John Wilding (Chair)
- Identifying and Managing the Psychosocial Aspects of Type 2 Diabetes Mellitus; Richard Holt (Faculty)
- Potential Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin: Interactive Case Discussion; Bernard Charbonnel (Faculty)
Combination of daclatasvir + sofosbuvir positive in ALLY-2 trial for co-infected HIV and hepatitis C patients- BMS28-Feb-2015
BMS announced results from ALLY-2 , a Phase III clinical trial evaluating the investigational once-daily combination of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) coinfected with HIV – a patient ...
Actavis and Medicines360 have announced the approval of Liletta (levonorgestrel-releasing intrauterine system) by the FDA for use by women to prevent pregnancy for up to three years. Liletta is placed in the uterus by a healthcare professional and ...
Regeneron Pharmaceuticals has announced that Eylea (aflibercept) injection has been approved by the European Commission for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo). The new indication ...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced ...
Biogen Idec and Swedish Orphan Biovitrum AB announced positive top-line results of the Kids B-LONG Phase III clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion ...
Sorin S.p.A. a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics Inc. a medical device company with core expertise in neuromodulation, announced their merger plan to create a new global leader in ...
FDA approves Toujeo (insulin glargine [rDNA origin]) for treatment of Type 1 and Type 2 Diabetes-Sanofi27-Feb-2015
Sanofi announced that the FDA approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be ...